Generic Reply just come in11 Oct 2023 15:10
Thank you for your message and apologies for the delay in our response.
The news about the launch of the PSE test and reimbursement code has been issued widely to media in the UK and the US and was covered by several mainstream newspapers/websites including The Times, The Daily Mail (mailonline in Money and Health sections) and the Sunday Express, some of which included content from interviews with OBD team members. Just as healthcare professionals and patient advocacy groups will want to look into the test and its features, so will the healthcare press. We anticipate that the test is likely to gain more traction with both the mainstream and healthcare media as more physicians order it, see patients benefit from it and in turn talk about it. We are continuing to encourage this to happen.
Whilst we aim to answer as many enquiries as possible, as a public company, we can only provide answers based on publicly available information. We can assure our shareholders that any important, price sensitive news will be released via RNS in a timely manner.
In order to see such news as soon as possible, please sign up for email alerts at https://www.oxfordbiodynamics.com/investors/news-events/email-alerts. We will also announce investor-focused webinars and other public events in advance by RNS, typically as part of financial results announcements.
You may also wish to follow OBD’s social media accounts (listed below) for other updates including publications and media. Our blog In the Loop provides longer-form posts for those interested in the Company, its products and technology – subscribe to receive notification of new blog posts at https://intheloop.oxfordbiodynamics.com/.
There is extensive information on the PSE test, including a technical overview and FAQs available on our dedicated website www.94percent.com.
Sign In
Follow the stocks
